Khudhur, S., Saleh, E., Alosami, M. (2023). The Impact of rs767455 and rs1061622 Polymorphisms on Treatment Outcomes in Iraqi Ankylosing Spondylitis Patients Taking Etanercept. The Egyptian Journal of Hospital Medicine, 90(2), 3488-3494. doi: 10.21608/ejhm.2023.291469
Shaimaa S. Khudhur; Eman S. Saleh; Mohammed H. Alosami. "The Impact of rs767455 and rs1061622 Polymorphisms on Treatment Outcomes in Iraqi Ankylosing Spondylitis Patients Taking Etanercept". The Egyptian Journal of Hospital Medicine, 90, 2, 2023, 3488-3494. doi: 10.21608/ejhm.2023.291469
Khudhur, S., Saleh, E., Alosami, M. (2023). 'The Impact of rs767455 and rs1061622 Polymorphisms on Treatment Outcomes in Iraqi Ankylosing Spondylitis Patients Taking Etanercept', The Egyptian Journal of Hospital Medicine, 90(2), pp. 3488-3494. doi: 10.21608/ejhm.2023.291469
Khudhur, S., Saleh, E., Alosami, M. The Impact of rs767455 and rs1061622 Polymorphisms on Treatment Outcomes in Iraqi Ankylosing Spondylitis Patients Taking Etanercept. The Egyptian Journal of Hospital Medicine, 2023; 90(2): 3488-3494. doi: 10.21608/ejhm.2023.291469
The Impact of rs767455 and rs1061622 Polymorphisms on Treatment Outcomes in Iraqi Ankylosing Spondylitis Patients Taking Etanercept
Background: Ankylosing spondylitis (AS) is inflammation of the sacroiliac joints and spine, associated with clinical symptoms such as pain and stiffness in the vertebral column, after which, in a considerable number of individuals, new bone growth occurs. Objective: The current research study attempted to find out whether the presence of SNPs in TNF receptor [TNFRSF1A (rs767455), TNFRSF1B (rs1061622)] encoding genes could influence patients' outcomes to etanercept in a specimen of Iraqi AS patients. Patients and methods: Sixty patients with established AS receiving only etanercept were selected to be enrolled in this research with a mean age of 40.75 ± 8.67 years, 51 patients of them were males and only 9 patients were females. Patients were classed as "responders" if just obtained a BASDAI 50 clinical response and as "non-responders" if they can't achieve a BASDAI 50 clinical elaboration after at least 6 months treatment. After PCR products amplification of purified blood DNA, TNF receptor (TNFRSF1A and TNFRSF1B) genes SNPs were established by Sanger sequencing. Results: The analysis of this study expressed that there was a significant incidence of TT genotype of rs1061622 (P = 0.022) in responder group, whereas the TG genotype of the same single nucleotide polymorphism (SNP) was considerably present in the group that did not respond (P = 0.002). Finally, a non-significant difference existed in alleles and genotypes frequency between responder and non-responder groups of rs767455 SNP in TNFRSF1A gene. Conclusions: The wild TT genotype of rs1061622 predicts etanercept responsiveness in ankylosing spondylitis patients. The TG genotype of the same SNP increases the probability of non-responding.